A Life Science Accelerator
501 Ventures is a Life Science Accelerator Providing Turnkey Solutions for IP Based Technologies
501 Ventures is an umbrella organization providing investment opportunities in asset-based subsidiaries while providing capital efficiency of shared talent and overhead
The 501 Ventures Competitive Advantage
Track record of company and asset exits in the industry:
Leadership team has deep understanding of big pharma’s needs to drive efficiency
Proven track record managing small and lean start-ups:
Search team performs extensive due dilligence identifying high priority requirements needed to get assets to next inflection point.
Comprehensive in-house clinical development experts:
The majority of clinical development is done in house without use of CROs decreasing the time and financial resources needed.
Pipeline
Compound
Preclinical
Phase 1
Phase 2
Phase 3
Drug-Device Combination to Manage External Bleeding
Bio 751
Stealth
Our team at 501 Ventures is comprised of entrepreneurs with executive leadership experience
- The shared model allows human capital and overhead to be distributed across 2-4 programs providing subsidiaries experienced talent and infrastructure at a fraction of the cost
- Capital raised in subsidiaries that have service arrangement with 501
- The majority of clinical work is done “in house” with minimal use of third party vendors providing time and financial savings
Meet Our Team
Meg Powell, Pharm. D.
Chief Executive Officer
Hazar Granko, PhD
Chief Development Officer
Dave Brown
Chief Strategy Officer
Jennifer Woods
VP Finance and Operations
Laura Malahias
VP Clinical Operations
